ANXA5 and triple-negative breast carcinoma: Moreover, we performed MTT (Supplementary Figure S3c) and Annexin V assays on an additional cell line, BT549, a triple-negative breast cancer model, to validate the activity of the compounds (Supplementary Figure S4).